Clinical trials
Patient Safety clinical trials
Below are recruiting patient safety clinical trials, each written for real people, not researchers. We’re tracking 1,353 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05798897RecruitingPhase 1
Study drug MT-601 for relapsed lymphoma patients
This early-phase trial tests MT-601 (an experimental treatment) in adults whose lymphoma has come back or didn’t respond to standard treatments. The study mainly checks safety, and it also looks for early signs that the treatment can shrink tumors.
Duarte, CaliforniaAges 18–100 - NCT05895981Recruiting
Sacral nerve stimulation for ulcerative colitis symptoms
This trial tests whether sacral nerve stimulation—a device that sends small electrical signals near nerves in the lower back—can be safe and helpful for ulcerative colitis. It is meant for people whose ulcerative colitis has not improved enough with medicines.
Xi'an, ShaanxiAges 18 years+ - NCT05906992RecruitingPhase 3
Testing CT-P53 versus Ocrevus for relapsing MS
This Phase 3 study compares CT-P53 with Ocrevus in people with relapsing-remitting multiple sclerosis (MS). It aims to see how well each treatment controls MS activity and to compare safety and study drug effects.
PoznanAges 18–55 - NCT05923905RecruitingPhase 4
Study of FB1006 for people with early ALS
This trial tests whether FB1006 is safe and works better than usual care for treating amyotrophic lateral sclerosis (ALS). It focuses on people with relatively early ALS and good breathing function.
Beijing, Beijing MunicipalityAges 18–80 - NCT06016920RecruitingPhase 1/Phase 2
HPV16 vaccine plus Keytruda for oropharyngeal cancer
This trial tests a new vaccine (VB10.16) combined with the immunotherapy Keytruda (pembrolizumab) for people with HPV16-positive oropharyngeal cancer that has spread or come back. The goal is to see if the combination helps shrink tumors or slow cancer growth.
OlomoucAges 18 years+ - NCT06073769Recruiting
Safety study of oral azacitidine for AML in Korea
This study is monitoring the safety of the drug oral azacitidine (also called Onureg) when given as maintenance therapy to adults with acute myeloid leukemia (AML). It is designed to track how well patients tolerate the medicine in real-world use in Korea.
SeoulAges 19 years+ - NCT06081062RecruitingPhase 3
Testing Fabagal in people with Fabry disease
This trial is testing a new enzyme replacement therapy called Fabagal for people with Fabry disease who have not had prior treatment. It aims to see if it helps with kidney, heart, or brain problems caused by the disease.
ManilaAges 8 years+ - NCT06120582RecruitingPhase 1/Phase 2
Gene therapy safety study for severe hemophilia B
This study tests a new gene therapy called ANB-002 for men with severe hemophilia B (factor IX levels at or below 2%). The goal is to see if it's safe and how well it might help your blood clot normally.
HomyelAges 18 years+ - NCT06141525Recruiting
Remote conditioning for safer heart bypass recovery
This study tests whether a simple, non-invasive treatment called remote ischemic conditioning (using a blood pressure cuff on your arm) can help patients recover better after off-pump heart bypass surgery. The goal is to see if it reduces complications and improves heart function.
Xi'an, ShaanxiAges 18–70 - NCT06145074RecruitingPhase 2
Testing propranolol before surgery for pancreatic cancer
This trial tests if taking propranolol (a blood pressure medication) before surgery helps treat pancreatic cancer that can be removed. It aims to see if the drug is safe and works well.
CopenhagenAges 18 years+ - NCT06199401Recruiting
Testing a new surgery for type A aortic tear
This trial tests a new surgical method (XJ-Procedure) for people with an acute tear in the upper part of the main artery from the heart (type A aortic dissection). It may offer a safer option for those needing 'Sun's procedure' surgery.
Xi'an, ShaanxiAges 18–70 - NCT06202027Recruiting
CRYSVITA safety and effectiveness in Korean patients
This study looks at the safety and effectiveness of CRYSVITA (burosumab) in real-world use among patients in South Korea. If you are already prescribed CRYSVITA for X-linked hypophosphatemia, your doctor may ask you to join this survey to help track how well it works and any side effects.
Wŏnju, Gangwon-doAges 1 day+ - NCT06204991RecruitingPhase 1
T-cell therapy for advanced melanoma
This trial tests a new treatment called ADP-TILIL7 for people with advanced melanoma. It uses your own immune cells (T-cells) that are taken from a tumor, multiplied in a lab, and then given back to you to fight the cancer. The goal is to see if this treatment is safe and works better than standard options.
HerlevAges 18–75 - NCT06225856RecruitingPhase 1
YY201 for advanced solid tumors and blood cancers
This trial tests a new drug, YY201, that targets a protein called STAT3, which may help certain advanced solid tumors and blood cancers. It is for people who have tried standard treatments without success.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06287229RecruitingPhase 1/Phase 2
CAR T therapy for B-cell ALL after initial treatment
This trial tests whether a special immune cell therapy (brexucabtagene autoleucel, or CAR T therapy) can help people with B-cell acute lymphocytic leukemia (ALL) after reducing the number of leukemia cells with a chemo-immunotherapy combination. It is for patients whose cancer has returned or is hard to treat, or for those newly diagnosed with a high-risk form of ALL.
Houston, TexasAges 18 years+ - NCT06305416RecruitingPhase 3
Ranibizumab for diabetic macular edema
This trial tests an injection called Ranibizumab (10 mg/ml) to treat diabetic macular edema, a condition where fluid builds up in the center of the retina and causes blurry vision. The goal is to see if the drug is safe and effective at improving vision.
DhakaAges 18 years+ - NCT06307925RecruitingPhase 1
HC010 for advanced solid tumors: a safety and early efficacy study
This trial is testing a new drug (HC010) for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe, how it works in the body, and whether it can shrink tumors.
Guangzhou, GuangdongAges 18–75 - NCT06321341RecruitingPhase 4
Testing Vespireit for chronic dizziness from autonomic dysfunction
This trial tests a new medication called Vespireit (prolonged-release buspirone) for people with chronic dizziness caused by a problem with the autonomic nervous system. The study aims to see if the drug helps reduce dizziness and improve quality of life.
BryanskAges 18–65 - NCT06389877RecruitingPhase 1/Phase 2
Testing BEAM-302 for alpha-1 antitrypsin deficiency
This trial tests a new treatment called BEAM-302, which aims to correct the genetic defect that causes alpha-1 antitrypsin deficiency. It may help prevent further lung and liver damage in people with the PiZZ mutation.
Birmingham, AlabamaAges 18–70 - NCT06403878RecruitingPhase 2
Chemo-immunotherapy before surgery for older adults with esophageal cancer
This trial tests whether giving chemotherapy and immunotherapy before surgery is safe and effective for older adults (70+) with a certain type of esophageal cancer. It aims to find a treatment approach that works well for patients who haven't had cancer treatment before.
ChengduAges 70–100 - NCT06411925RecruitingPhase 4
Atock Dry Syrup for children with acute bronchitis
This trial tests a new cough syrup (Atock Dry Syrup) for children with acute bronchitis. If your child has a bad cough, wheezing, and symptoms started in the last 2 days, this treatment may help ease their symptoms.
SeoulAges 6 months–11 years - NCT06478225Recruiting
Cell therapy for advanced pancreatic cancer
This trial tests a new cell therapy (BGT007H) for people with advanced pancreatic cancer that has not responded to earlier treatments. The goal is to see if it is safe and can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06479863RecruitingEarly Phase 1
Testing a new drug combo for inclusion body myositis
This trial tests a combination of two investigational drugs (pozelimab and cemdisiran) to see if they can help people with sporadic inclusion body myositis, a muscle disease that causes progressive weakness. If the drugs work, they may slow down the disease and help you stay stronger longer.
Austin, TexasAges 45–75 - NCT06519552RecruitingPhase 1
Gene therapy study for adults with MPS type I
This study tests a new gene therapy called JWK008 for adults with MPS type I. The goal is to see if it is safe and can help improve symptoms. You may be able to join if you are 18 or older and have not had serious side effects from enzyme replacement therapy.
Chengdu, SichuanAges 18 years+
Hear when a new Patient Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for patient safety?
- Yes. Clin2 currently lists 1,353 recruiting patient safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a patient safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a patient safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.